US5348974A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
Assignee: Bristol Myers Squibb Co
•
Filing: 1993-02-10
•
Granted: 1994-09-20
•
Expires: 2013-02-10
Abstract
Abstract This invention relates to the use of tocotrienol, gamma-tocotrienol and delta-tocotrienol in reducing hypercholesterolemia, hyperlipidemia and thromboembolic disorders in mammals. The isolation of these tocotrienols from natural sources and their chemical synthesis is disclosed. The present invention also relates to prodrugs and pharmaceutical compositions of gamma-tocotrienol, delta-tocotrienol and tocotrienol and uses thereof.
Inventors
- 👤 John J. Wright
- 👤 Bradley C. Pearce
- 👤 Rex Parker
- 👤 Asaf A. Qureshi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 02:38
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61K31/352; A61K31/353; A61K31/355; A61P; A61P3/00; A61P3/06; A61P43/00; A61P7/00; A61P7/02; C; C07; C07D; C07D311/00; C07D311/02; C07D311/04; C07D311/58; C07D311/70; C07D311/72
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
52 words
A method of reducing, in a bird or a mammal, the platelet aggregation to adenosine diphosphate, epinephrine or Collagen in platelet rich plasma and whole blood which comprises administering to such bird or mammal a safe and effective amount of substantially pure gamma-tocotrienol, substantially pure delta-tocotrienol, substantially pure tocotrienol, or mixtures thereof.
Claim 2
Independent Claim
52 words
A method of reducing, in a bird or a mammal, the platelet aggregation to adenosine diphosphate, epinephrine or Collagen in platelet rich plasma and whole blood which comprises administering to such bird or mammal a safe and effective amount of substantially pure gamma-tocotrienol, substantially pure delta-tocotrienol, substantially pure tocotrienol, or mixtures thereof.
Claim 3
Independent Claim
46 words
A method of reducing, in a bird or mammal, thromboxane A 2 and platelet factor 4 levels providing antithrombotic effectiveness which comprises administering to such bird or mammal a safe and effective amount of substantially pure gamma-tocotrienol, substantially pure delta-tocotrienol, substantially pure tocotrienol, or mixtures thereof.
Claim 4
Independent Claim
46 words
A method of reducing, in a bird or mammal, thromboxane A 2 and platelet factor 4 levels providing antithrombotic effectiveness which comprises administering to such bird or mammal a safe and effective amount of substantially pure gamma-tocotrienol, substantially pure delta-tocotrienol, substantially pure tocotrienol, or mixtures thereof.
Claim 5
Independent Claim
50 words
A method of reducing, in a bird or a mammal, the platelet aggregation to adenosine diphosphate, epinephrine or Collagen in platelet rich plasma and whole blood which comprises administering to such bird or mammal a safe and effective amount of the prodrug of gamma-tocotrienol, delta-tocotrienol or tocotrienol, or mixtures thereof.
Claim 6
Independent Claim
50 words
A method of reducing, in a bird or a mammal, the platelet aggregation to adenosine diphosphate, epinephrine or Collagen in platelet rich plasma and whole blood which comprises administering to such bird or mammal a safe and effective amount of the prodrug of gamma-tocotrienol, delta-tocotrienol or tocotrienol, or mixtures thereof.
Claim 7
Independent Claim
45 words
A method of reducing, in a bird or a mammal, thromboxane A 2 and platelet factor 4 levels providing antithrombotic effectiveness which comprises administering to such bird or mammal a safe and effective amount of the prodrug of gamma-tocotrienol, delta-tocotrienol or tocotrienol, or mixtures thereof.
Claim 8
Independent Claim
45 words
A method of reducing, in a bird or a mammal, thromboxane A 2 and platelet factor 4 levels providing antithrombotic effectiveness which comprises administering to such bird or mammal a safe and effective amount of the prodrug of gamma-tocotrienol, delta-tocotrienol or tocotrienol, or mixtures thereof.
Claim 9
Independent Claim
18 words
The method of any one of claims 1, 2, 3 and 4 wherein the tocotrienol is the d-isomer.
Claim 10
Independent Claim
21 words
The method of any one of claims 1, 2, 3 and 4 wherein the tocotrienol is the d, l racemic mixture.
References Cited (Backward Citations)
GB2117381A
Cited
US4603142A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-09-19 | 1998-03-21 | 1998-09-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-09-19 | 2002-03-21 | 2002-09-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-09-19 | 2006-03-21 | 2006-09-20 | $7700.00 | Window Closed / Lapsed |